Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Patel, JN; Jiang, C; Hertz, DL; Mulkey, FA; Friedman, PN; Halabi, S; Ratain, MJ; Morris, MJ; Small, EJ; Owzar, K; Kelly, WK; McLeod, HL

Published Date

  • October 1, 2014

Published In

  • Clinical Research (Excluding Clinical Trials)

Published By

Digital Object Identifier (DOI)

  • 10.1158/1538-7445.am2014-3841

Conference Name

  • Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA